(Q35011904)

5 August 2017

1 reference

title

Future potential of thymidylate synthase inhibitors in cancer therapy (English)

1 reference

5 August 2017

Norman L Lehman

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Expert Opinion on Investigational Drugs

5 August 2017

published in

1 reference

5 August 2017

volume

11

1 reference

5 August 2017

issue

12

1 reference

5 August 2017

page(s)

1775-1787

1 reference

The catalytic mechanism and structure of thymidylate synthase

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

E2F: a link between the Rb tumor suppressor protein and viral oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

On the nature of thymineless death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Inhibition of 2-desamino-2-methyl-10-propagyl-5,8-dideazafolic acid cytotoxicity by 5,10-dideazatetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate pools.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Thymineless death in colon carcinoma cells is mediated via fas signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2'-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Fluorouracil: active in ZD1694 (tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Biological and biochemical properties of new anticancer folate antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Potocytosis: Sequestration and Transport of Small Molecules by Caveolae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

The role of interferon-α as a modulator of fluorouracil and leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Combination studies with 3'-azido-3'-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

The alpha folate receptor is highly activated in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Pharmacogenetics: the Dx perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

The development and clinical use of trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Classical and novel retinoids: their targets in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

The proteasome: a new target for novel drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1775

10.1517/13543784.11.12.1775

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference